PLGA based drug delivery systems: Promising carriers for wound healing activity

Asadi

J of Applied Polymer Sci

2018

Bioactive wound dressings from poly(vinyl alcohol) (PVA) and zein nanoparticles (NPs) loaded with diclofenac (DLF) were prepared successfully by the single jet electrospinning method. DLF‐loaded zein NPs with an average diameter of ∼228 nm were prepared using anti‐solvent precipitation method. The formulation of zein:DLF 1:1 exhibited optimum encapsulation efficiency of 47.80%. The NPs were characterized by dynamic light scattering, zeta‐potential measurement, and differential scanning calorimetry. In vitro, drug release profiles of the DLF‐loaded zein NPs, and PVA–zein NPs were also studied within 120 h and showed the release efficiency of nearly 80% from zein NPs. A more controlled release of DLF was achieved by embedding the zein NPs in the PVA nanofibers. Fourier transform infrared spectroscopy was used to analyze possible interactions between different components of the fabricated dressings. The mechanical properties of the developed dressings were also evaluated using uniaxial tensile testing. Young's modulus (E) of the dressings decreased after inclusion of zein NPs within the PVA nanofibers. Moreover, fibroblast culturing experiments proved that the composite dressings supported better cell attachment and proliferation compared to PVA nanofibers, by exhibiting moderate hydrophilicity. The results suggested that the electrospun composite dressing of PVA nanofibers and zein NPs is a promising topical drug‐delivery system and have a great potential for wound healing application. © 2018 Wiley Periodicals, Inc. J. Appl. Polym. Sci. 2018, 135, 46643.

Section: Introductionmentioning

confidence: 99%

Zein nanoparticle‐embedded electrospun PVA nanofibers as wound dressing for topical delivery of anti‐inflammatory diclofenac

Asadi

J of Applied Polymer Sci

2018

“…The solution was then analyzed by UV-vis (UV-Visible-V-730 UV-Visible Spectrophotometer, Jasco, (Cremella, (LC), Italy) following the signal at 426 nm. The quantity of curcumin-loaded was obtained through the Beer-Lambert law using 58,547 dm 3 •mol −1 •cm −1 as the molar extinction coefficient of curcumin in DMSO [41]. All experiments were performed in triplicate.…”

Section: Entrapment Efficiency (%ï) Of Cur Inside Mpsmentioning

confidence: 99%

“…In recent decades, polymeric microparticles (MPs) have been widely used as drug delivery systems for the controlled release of small molecules, proteins or peptides [1][2][3][4][5]. The reason of this great diffusion is due to several attractive features such as the use of non-laborious techniques [6], low production costs [7], simplicity in industrial scale-up [8] and possibilities of different ways of administration (oral, ocular, parental, inhalation) [9,10].…”

Section: Introductionmentioning

confidence: 99%

Tunable Release of Curcumin with an In Silico-Supported Approach from Mixtures of Highly Porous PLGA Microparticles

et al. 2020

In recent years, drug delivery systems have become some of the main topics within the biomedical field. In this scenario, polymeric microparticles (MPs) are often used as carriers to improve drug stability and drug pharmacokinetics in agreement with this kind of treatment. To avoid a mere and time-consuming empirical approach for the optimization of the pharmacokinetics of an MP-based formulation, here, we propose a simple predictive in silico-supported approach. As an example, in this study, we report the ability to predict and tune the release of curcumin (CUR), used as a model drug, from a designed combination of different poly(d,l-lactide-co-glycolide) (PLGA) MPs kinds. In detail, all CUR–PLGA MPs were synthesized by double emulsion technique and their chemical–physical properties were characterized by Mastersizer and scanning electron microscopy (SEM). Moreover, for all the MPs, CUR encapsulation efficiency and kinetic release were investigated through the UV–vis spectroscopy. This approach, based on the combination of in silico and experimental methods, could be a promising platform in several biomedical applications such as vaccinations, cancer-treatment, diabetes therapy and so on.

Drug Development Research

“…Among the various biodegradable polymers for fabrication of polymeric nanoparticles, poly‐lactide‐co‐glycolide (PLGA) is a good candidate for the encapsulation of OXC due to its well defined and flexible formulation techniques (Danhier et al., ; D. Ding & Zhu, ). PLGA is also approved by the US Food and Drug Administration (FDA) and European Medicine Agency (EMA) to utilizing in drug‐delivery purposes (Chereddy, Vandermeulen, & Préat, ; Jose et al., ) due to its biocompatible, biodegradable, and nontoxic properties (Eren et al., ; Ji et al., ). Moreover, the degradation period of PLGA can be varied from days to months due to alteration in its molecular weight and copolymer ratio (Martins, Sousa, Araújo, & Sarmento, ).…”

Section: Introductionmentioning

confidence: 99%

Development and characterization of oxaceprol‐loaded poly‐lactide‐co‐glycolide nanoparticles for the treatment of osteoarthritis

Alarçin

Demirbağ

Karslı-Çeppioğlu

et al. 2020

Oxaceprol is well-defined therapeutic agent as an atypical inhibitor of inflammation in osteoarthritis. In the present study, we aimed to develop and characterize oxaceprol-loaded poly-lactide-co-glycolide (PLGA) nanoparticles for intra-articular administration in osteoarthritis. PLGA nanoparticles were prepared by doubleemulsion solvent evaporation method. Meanwhile, a straightforward and generally applicable high performance liquid chromatography method was developed, and validated for the first time for the quantification of oxaceprol. To examine the drug carrying capacity of nanoparticles, varying amount of oxaceprol was entrapped into a constant amount of polymer matrix. Moreover, the efficacy of drug amount on nanoparticle characteristics such as particle size, zeta potential, morphology, drug entrapment, and in vitro drug release was investigated. Nanoparticle sizes were between 229 and 509 nm for different amount of oxaceprol with spherical smooth morphology. Encapsulation efficiency ranged between 39.73 and 63.83% by decreasing oxaceprol amount. The results of Fourier transform infrared and DSC showed absence of interaction between oxaceprol and PLGA. The in vitro drug release from these nanoparticles showed a sustained release of oxaceprol over 30 days. According to cell culture studies, oxaceprol-loaded nanoparticles had no cytotoxicity with high biocompatibility. This study was the first step of developing an intra-articular system in the treatment of osteoarthritis for the controlled release of oxaceprol. Our findings showed that these nanoparticles can be beneficial for an effective treatment of osteoarthritis avoiding side effects associated with oral administration. K E Y W O R D Sintra-articular injection, nanoparticle, osteoarthritis, oxaceprol, PLGA